期刊文献+

三维试验提取法测定革兰阴性杆菌高产Ⅰ型β—内酰胺酶初步研究 被引量:5

下载PDF
导出
摘要 目的:了解革兰阴性杆菌高产Ⅰ型β—内酰胺酶(AmpCs)与超广谱β—内酰胺酶(ESBLS)的发生率。方法:应用三维试验提取法,以头孢西丁为底物测定细菌高产AmpCs;应用美国临床实验室标准化委员会(NCCLS)推荐的纸片扩散法表型确证试验测定ESBLs。结果:381株革兰阴性杆菌AmpCs和ESBLs的发生率分别为:大肠埃希菌2.0%(2/102)、31.4%(32/102),肺炎克雷伯菌1.4%(2/142)、38.0%(54/142),阴沟肠杆菌57.4%(31/54)、66.7%(36/54),粘质沙雷菌53.8%(7/13)、61.5%(8/13),构橼酸杆菌属37.5%(6/16)、50%(8/16),变形杆菌属7.1%(1/14)、28.6%(4/14),铜绿假单胞菌16.7(5/30)、33.3%(10/30),不动杆菌属11.1%(1/9)、66.7%(6/9)。结论:革兰阴性杆菌均有不同程度产高产Ⅰ型β—内酰胺酶(AmpCs)及超广谱β—内酰胺酶(ESBLs),对其进行监测,有助于临床合理使用抗生素。
出处 《检验医学教育》 2002年第2期42-44,共3页
  • 相关文献

参考文献7

  • 1Itokauzu GS,,Quinn JP,Bell-Dixon C, et al.Antimicrobial resistance rates among aerobic Gram negative bacillus recovered from patients in intensive care units: evaluation of a national postmarketing sureillanee program[].Clinical Infectious Diseases.1996
  • 2Coudron PE,Moland ES,Thomson KS.Occurrence and Detection of AmpC Beta-lactamases among Eschericha coli、 Klebsiella pneumoniae and Proteus mirabilis[].Journal of Clinical Microbiology.2000
  • 3Livemove,DM.Beta-lactamases in laboratory and chinical resistance[].Clinical Microbiology Reviews.1995
  • 4Jones RN,Baquero F,Privitera G, et al.Inducible Beta-lactamase-mediated resistence to third-generation Cephalosopsins[].Clinical Microbiology and Infection.1997
  • 5Banernfeind A,Schneider I,JungWirth R, et al.A novel type of AmpC Beta-lactamase, Acc-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia[].Antimicrobial Agents and Chemotherapy.1999
  • 6Horii T,Arakawa Y,Ohta M,et al.Plasmid-mediated AmpC-type beta-lactamase isolated from Klebsiella pneumoniae confers resistance to broad-spectrum beta-lactams, including moxalactam[].Antimicrobial Agents and Chemotherapy.1993
  • 7Ardanuy C,Linares J,Dominguez MA,et al.Outer membrane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems[].Antimicrobial Agents and Chemotherapy.1998

同被引文献25

  • 1王金良.密切注视鲍曼不动杆菌的耐药发展趋势[J].中华检验医学杂志,2005,28(4):355-356. 被引量:194
  • 2[5]Mahoub S,Ahmed J,Glatt AE.Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii.Am J Infect Corntrol,2002,30 (7):386.
  • 3[7]Stephane C,Nathalie C,Eric E,et al.AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains.J Anti Microb Chemother,2003,52:629.
  • 4[8]Clark RB.Lmipenem resistance among acinetobacter baumannii:association with reduced expression of a 33-36 kDa outer membrane protein.J Antimicrob Chemother,1996,38:245.
  • 5[9]Donald HM,Scaife W,Amyes SG.et al.Sequence analysis of ARI-1,a noval OXA-lactamase,responsible for inipenem resistance in Acinetobacter baumannii 6B92.Antimicrob Agents Chemother,2000,44:196.
  • 6Courvalin P.Plasmid-mediated 4-quinolone resistance:a real or apparent absence [J].Antimicrob Agents Chemother,1990,34 (5):681
  • 7National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial susceptibility testing.M100-S9,Pennsylvania [S].NCCLS,1999,19:36,75
  • 8汪家政 范明.蛋白质技术手册[M].北京:科学出版社,2002(第一版).51-54.
  • 9Vahaboglu H, Ozturk R, Akbal H, et al. Practical approach for detection and identification of OXA-10-derived ceftazidime-hydrolyzing extended spectrum β lactamases[J]. J Clin Microbiol, 1998,36:827.
  • 10Poirel L, Thomas IL, Naas T, et al. Biochemical sequence analyses of GES-1, a novel class A extended spectrum βlactamase, and the class 1 ntegron in 52 from Klesiella pneumoniae[J]. Antimicrob Agents Chemother, 2000,44: 622.

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部